Neutrophil-to-lymphocyte ratio in head and neck cancer

Journal of Medical Imaging and Radiation Oncology

Volumn 59, Issue 4, 2015, Pages 514-519

  Haddad, Carol R ^a   Guo, Linxin ^a   Clarke, Stephen ^a,b   Guminski, Alex ^a,b   Back, Michael ^a,b   Eade, Thomas ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

head and neck cancer; inflammation; neutrophil to lymphocyte ratio; NLR; radiotherapy

Indexed keywords

CISPLATIN; BIOLOGICAL MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALE; METASTASIS FREE SURVIVAL; MULTIPLE CYCLE TREATMENT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMOKING; VERY ELDERLY; BLOOD; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; HEAD AND NECK TUMOR; LEUKOCYTE COUNT; LYMPHOCYTE; MIDDLE AGED; MORTALITY; NEUTROPHIL; NEW SOUTH WALES; PATHOLOGY; PREVALENCE; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; BIOMARKERS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; LEUKOCYTE COUNT; LYMPHOCYTES; MALE; MIDDLE AGED; NEUTROPHILS; NEW SOUTH WALES; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84938213919     PISSN: 17549477     EISSN: 17549485     Source Type: Journal    
DOI: 10.1111/1754-9485.12305     Document Type: Article

References (24)

1. Jarnicki A, Putoczki T, Ernst M,. Stat3: Linking inflammation to epithelial cancer-more than a 'gut' feeling? Cell Div 2010; 5: 1-5.
2. McMillan D,. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care 2009; 12: 223-226.
3. Kao SCH, Pavlakis N, Harvie R, et al. High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 2010; 16: 5805-5813.
4. Porrata LF, Ristow K, Habermann T, et al. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Haematol 2010; 85: 896-899.
5. Bhatti I, Peacock O, Lloyd G, et al. Preoperative haematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: Neutrophil-lymphocyte ratio versus platelet-lymphocyte ratio. Am J Surg 2010; 200: 197-203.
6. An X, Ding P, Li Y, Wang F, et al. Elevated neutrophils to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers 2010; 15: 516-522.
7. Liu H, Liu G, Bao Q, et al. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in rectal carcinoma. J Gastrointest Cancer 2010; 41: 116-120.
8. Shimada H, Takiguchi N, Kainuma O, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer 2010; 13: 170-176.
9. Ang KK, Harris J, Wheeler R, et al. Human Papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
10. An X, Ding PR, Wang FH, et al. Elevated neutrophil to lymphocyte ratio predicts poor prognosis in nasopharyngeal carcinoma. Tumour Biol 2011; 32: 317-324.
11. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005; 91: 181-184.
12. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ration of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007; 73: 215-220.
13. Gomez D, Farid S, Malik HZ, et al. Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg 2008; 32: 1757-1762.
14. Halazun KJ, Aldoori A, Malik HZ, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection of colorectal liver metastases. Eur J Surg Oncol 2008; 34: 55-60.
15. Cho HB, Hur HW, Kim SW, et al. Pre-treatment neutrophils to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol Immunother 2000; 58: 15-23.
16. Gomez D, Morris-Stiff G, Toogood GJ, et al. Impact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma. J Surg Oncol 2008; 97: 513-518.
17. Kishi Y, Kopetz S, Chun YS, et al. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol 2009; 16: 614-622.
18. Halazun KJ, Hardy MA, Rana AA, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009; 250: 141-151.
19. Sarraf KM, Belcher E, Raevsky E, et al. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009; 137: 425-428.
20. Ding PR, An X, Zhang RX, et al. Elevated preoperative neutrophil to lymphocyte ratio predicts risk of recurrence following curative resection for stage IIA colon cancer. Int J Colorectal Dis 2010; 25: 1427-1433.
21. Leitch EF, Chakrabarti M, Crozier JEM, et al. Comparison of the prognostic value of selected markers of the systemic inflammatory response in patients with colorectal cancer. Br J Cancer 2007; 97: 1266-1270.
22. Rashid F, Waraich N, Bhatti I, et al. A pre-operative elevated neutrophil: Lymphocyte ratio does not predict survival from oesophageal cancer resection. World J Surg Oncol 2010; 8: 1-10.
23. Tamahne UU, Aneja S, Montgomery D, et al. Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome. Am J Cardiol 2008; 102: 653-657.
24. Trellakis S, Bruderek K, Dumitru CA, et al. Polymorphonuclear granulocytes in human head and neck cancer: Enhanced inflammatory activity, modulation by cancer cells and expansion in advanced disease. Int J Cancer 2011; 129: 2183-2193.